Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 813160

Next Previous
Drug Profile

BMS 813160

Alternative Names: BMS-813160

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Icahn School of Medicine at Mount Sinai; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Antihyperglycaemics; Antineoplastics; Pyrazoles; Small molecules; Triazines; Uroprotectives
  • Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic nephropathies; Liver cancer; Non-small cell lung cancer
  • Phase I/II Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 14 Jun 2023 Bristol-Myers Squibb completes a Phase-I/II clinical trials in Colorectal cancer and Panceratic Cancer (Combination therapy, Metastatic disease, Late-stage disease) in USA, Australia, Spain, Canada, Germany, Belgium (PO) (EudraCT2017-001725-40) (NCT03184870)
  • 14 Jun 2023 Bristol-Myers Squibb completes a Phase-I/II clinical trials in Colorectal cancer and Panceratic Cancer (Monotherapy, Metastatic disease, Late-stage disease) in USA, Australia, Spain, Canada, Germany, Belgium (PO) (EudraCT2017-001725-40) (NCT03184870)
  • 26 Jul 2022 BMS 813160 is still in phase I/II trials for Liver cancer (Combination therapy, Neoadjuvant therapy) in USA (NCT04123379)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top